Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Després J‐P, Lemieux I, Salomon H, Delaval D (CHUL Research Center, Ste‐Foy, Québec, Laval Hospital Research Center, Ste‐Foy, Québec, Canada and Laboratoires Fournier, Garches, France). Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial. J Intern Med 2002; 251: 490–499. Background. Studies have suggested that raising low levels of high‐density lipoprotein cholesterol (HDL‐C) may be an important target for the prevention of coronary heart disease. Objective. To compare the ability of micronized fenofibrate and atorvastatin to increase plasma HDL‐C levels. Design. Multicentre, randomized open‐label study. Settings. The study was conducted in 19 centres across the UK and Canada. Subjects. One hundred and eighty‐one patients were randomized and the full analysis set included 165 nondiabetic patients with low HDL‐C (women <46 mg dL−1, i.e. 1.2 mmol L−1 and men <43 mg dL−1, i.e. 1.1 mmol L−1): 86 patients in the atorvastatin group and 79 patients in the micronized fenofibrate group. Interventions. Micronized fenofibrate (200 mg day−1, 87 patients) or atorvastatin (10 mg day−1, 94 patients) for a period of 12 weeks. Main outcome measures. Percent change in HDL‐C levels. Results. After 12 weeks of treatment, the mean percent change from baseline in HDL‐C was significantly higher in the micronized fenofibrate group (13.3%) compared with the atorvastatin group (5.3%, P=0.0003). The magnitude of such relative change was inversely related to the baseline HDL‐C levels only in the micronized fenofibrate group. Furthermore, in the fenofibrate treatment group, 50.9% of the patients (29 of 57 patients) with a baseline HDL‐C <40 mg dL−1 achieved a plasma HDL‐C level above 40 mg dL−1 after 12 weeks of treatment versus 27.9% of the patients (19 of 68 patients) in the atorvastatin group (P=0.01). Conclusions. On the basis of (1) the greater impact of fenofibrate than atorvastatin on HDL‐C levels and (2) the greater proportion of dyslipidemic patients achieving HDL‐C levels above 40 mg dL−1 with fenofibrate than atorvastatin, it is suggested that micronized fenofibrate should be considered as a good therapeutic option to treat dyslipidemic patients with low HDL‐C and moderately elevated LDL‐C concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
Lemieux, I., Pascot, A., Couillard, C., Lamarche, B., Tchernof, A., Alméras, N., Bergeron, J., Gaudet, D., Tremblay, G., Prud’homme, D., et al. (2000) · Circulation · doi:10.1161/01.cir.102.2.179 · Cited by 937
Self-citationAssmann, G., & Schulte, H. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90550-i · Cited by 872
Fruchart, J.-C., Duriez, P., & Staels, B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00007 · Cited by 425
Prevalence of risk factors in men with premature coronary artery disease
Genest, J. J., McNamara, J. R., Salem, D. N., & Schaefer, E. J. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90924-a · Cited by 243
Cited by
Walldius, G., & Jungner, I. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01276.x · Cited by 396
Barter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p002816 · Cited by 259
Mohty, D., Pibarot, P., Després, J.-P., Côté, C., Arsenault, B., Cartier, A., Cosnay, P., Couture, C., & Mathieu, P. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.154989 · Cited by 181
Keating, G. M., & Croom, K. F. (2007) · Drugs · doi:10.2165/00003495-200767010-00013 · Cited by 169
Wang, T.-D., Chen, W.-J., Lin, J.-W., Cheng, C.-C., Chen, M.-F., & Lee, Y.-T. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00296-x · Cited by 125
Metadata
- Authors
- Després, J. ‐., Lemieux, I., Salomon, H., & Delaval, D.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2002-05-22
- Volume
- 251
- Issue
- 6
- Pages
- 490-499
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2077338443
- Cited by
- 44
- References
- 9
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial. https://app.cochat.ai/papers/10.1046/j.1365-2796.2002.00988.x
- The paper
- Després, J. ‐., Lemieux, I., Salomon, H., & Delaval, D. (2002). Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial. Journal of Internal Medicine. https://doi.org/10.1046/j.1365-2796.2002.00988.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.